SCHEMBL2268299

SCHEMBL2268299

O=Cc1c[nH]c2cnccc12

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 1/20 0.62
CDK9 P50750 1/20 0.62
HASPIN Q8TF76 1/20 0.62
CYP2A6 P11509 2/20 0.56
IMPDH2 P12268 1/20 0.56
DYRK1A Q13627 9/20 0.51
NFATC1 O95644 6/20 0.51
GSK3B P49841 4/20 0.51
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
PDPK1 O15530 1/20 0.45
TGFBR1 P36897 1/20 0.45
IKBKE Q14164 1/20 0.45
PLG P00747 1/20 0.44
PLAU P00749 1/20 0.44
CDK2 P24941 2/20 0.43
DYRK1B Q9Y463 2/20 0.43
IGF1R P08069 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29664462 1.00 CCNT1 (0.62) CCNT1CDK9HASPINCYP2A6IMPDH2
Hydrochloric Acid SCHEMBL3831446 0.98 CCNT1 (0.60) CCNT1CDK9HASPINCYP2A6IMPDH2
SCHEMBL2263957 0.85 CCNT1 (0.62) CCNT1CDK9HASPINCYP2A6IMPDH2
SCHEMBL27773730 0.81 DYRK1A (0.51) CCNT1CDK9HASPINDYRK1ANFATC1
SCHEMBL4268145 0.77 CCNT1 (0.65) CCNT1CDK9HASPINDYRK1ANFATC1
SCHEMBL4268142 0.77 CCNT1 (0.65) CCNT1CDK9HASPINDYRK1ANFATC1
SCHEMBL3594684 0.76 CCNT1 (0.56) CCNT1CDK9HASPINCYP2A6IMPDH2
SCHEMBL26700908 0.75 CCNT1 (0.58) CCNT1CDK9HASPINCYP2A6IMPDH2
3-Formylindole SCHEMBL29082887 0.74 CYP2A6 (0.77) CCNT1CDK9HASPINCYP2A6IMPDH2
SCHEMBL23600353 0.74 CGAS (0.51) CCNT1CDK9HASPINDYRK1ANFATC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155398-A1 HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS DAIICHI SANKYO COMPANY, LIMITED (JP) 2014-06-05 US claimed
US-20260092034-A1 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME KULEON LLC (US) 2026-04-02 US disclosed
US-20250340513-A1 NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS KULEON LLC (US) 2025-11-06 US disclosed
US-12441683-B2 7-methyl indole analogs and dosage forms containing the same Kuleon, LLC (US) 2025-10-14 US disclosed
US-20250282722-A1 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME KULEON LLC (US) 2025-09-11 US disclosed
US-12344582-B2 Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression Kuleon, LLC (US) 2025-07-01 US disclosed
US-12275701-B2 Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators Kuleon, LLC (US) 2025-04-15 US disclosed
US-20250091991-A1 MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION Kuleon, LLC (US) 2025-03-20 US disclosed
US-12187678-B2 Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators Kuleon, LLC (US) 2025-01-07 US disclosed
US-20240409542-A1 NOVEL COMPOUNDS SITRYX THERAPEUTICS LIMITED (GB) 2024-12-12 US disclosed
EP-1732566-A2 6-AZAINDOLE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2006-12-20 EP disclosed
WO-2005097129-A2 6-AZAINDOLE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-10-20 WO disclosed
EP-0715628-B1 SUBSTITUTED AZAINDOLYLIDENE COMPOUNDS AND PROCESS FOR THEIR PREPARATION PHARMACIA ITALIA SPA (IT) 2002-10-02 EP disclosed
EP-0626963-B1 VINYLENE-AZAINDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION PHARMACIA & UPJOHN SPA (IT) 1999-06-09 EP disclosed
US-5663346-A ENZYME INHIBITORS PHARMACIA S.P.A. (IT) 1997-09-02 US disclosed
EP-0715628-A1 SUBSTITUTED AZAINDOLYLIDENE COMPOUNDS AND PROCESS FOR THEIR PREPARATION PHARMACIA & UPJOHN S.p.A. (IT) 1996-06-12 EP disclosed
WO-1996000226-A1 SUBSTITUTED AZAINDOLYLIDENE COMPOUNDS AND PROCESS FOR THEIR PREPARATION PHARMACIA S.P.A. (IT) 1996-01-04 WO disclosed
US-5397787-A Tyrosine kinase inhibitors FARMITALIA CARLO ERBA S.R.L. (IT) 1995-03-14 US disclosed
EP-0626963-A1 VINYLENE-AZAINDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION PHARMACIA & UPJOHN S.p.A. (IT) 1994-12-07 EP disclosed
WO-1994014808-A1 VINYLENE-AZAINDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION FARMITALIA CARLO ERBA SRL (IT) 1994-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092034-A1 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME HTR2C, HTR7, HTR6 CCNT1 2860/4885CDK9 1208/4885HASPIN 1272/4885
US-20250282722-A1 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME HTR7, HTR2C, HTR1A CCNT1 2199/4885CDK9 2229/4885HASPIN 788/4885
US-12441683-B2 7-methyl indole analogs and dosage forms containing the same HTR7, HTR2C, HTR1A CCNT1 2199/4885CDK9 2229/4885HASPIN 788/4885
US-12275701-B2 Neuroplastogens and non-hallucinogenic serotonin 5-HT2A receptor modulators HTR2A, HTR2C, HTR1A CCNT1 3856/4885CDK9 4194/4885HASPIN 436/4885
US-12187678-B2 Methods of treating psychological disorders through the administration of serotonin 5-HT2C receptor modulators HTR2C, HTR2A, HTR3B CCNT1 4694/4885CDK9 4590/4885HASPIN 547/4885
US-20250340513-A1 NEUROPLASTOGENS AND NON-HALLUCINOGENIC SEROTONIN 5-HT2A/2C RECEPTOR MODULATORS HTR2A, HTR2C, HTR3A CCNT1 3900/4885CDK9 4071/4885HASPIN 453/4885
US-20240409542-A1 NOVEL COMPOUNDS CD47, GPR119, LRBA CCNT1 2777/4885CDK9 2082/4885HASPIN 3310/4885
US-12344582-B2 Mixed serotonin 5-HT2A/2C receptor agonists and methods for treating pain and depression HTR2A, HTR2C, HTR3A CCNT1 4625/4885CDK9 4771/4885HASPIN 1454/4885
US-20250091991-A1 MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION HTR2A, HTR2C, HTR3A CCNT1 4625/4885CDK9 4771/4885HASPIN 1454/4885
US-20140155398-A1 HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS MAP3K1, JAK2, AKT1 CCNT1 445/4885CDK9 174/4885HASPIN 643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.